Cannabigerol shows promise in reducing anxiety and stress, study finds

Whether the phytocannabinoid cannabigerol impacted mood, stress, and anxiety and caused any related adverse effects of cognitive or motor impairment.

Ionis outlines Phase 3 data for rare disease drug, preps for another potential launch

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 1, 2024

Nestlé Health Science plots next steps for C. diff drug Vowst after robust uptake

After a better-than-expected launch, Nestlé Health Science is planning its next commercialization moves for Vowst, an oral pill to treat recurring Clostridioides difficile, or C.

March 29, 2024

Opinion | No-Shows Have Got to Go!

Fred Pelzman of Weill Cornell Internal Medicine Associates and weekly blogger for MedPage Today, follows what’s going on in the world of primary care medicine

August 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.